Investigation of Proposed Activity of Clarithromycin at GABA_A Receptors Using [¹¹C]Flumazenil PET

Abstract

Clarithromycin is a potential treatment for hypersomnia acting through proposed negative allosteric modulation of GABA A receptors. We were interested whether this therapeutic benefit might extend to Parkinson's disease (PD) patients because GABAergic neurotransmission is implicated in postural control. Prior to initiating clinical studies in PD patients, we wished to better understand clarithromycin's mechanism of action. In this work we investigated whether the proposed activity of clarithromycin at the GABA A receptor is associated with the benzodiazepine binding site using in vivo [ 11 C]flumazenil positron emission tomography (PET) in primates and ex vivo [ 3 H]flumazenil autoradiography in rat brain. While the studies demonstrate that clarithromycin does not change the K d of FMZ, nor does it competitively displace FMZ, there is preliminary evidence from the primate PET imaging studies that clarithromycin delays dissociation and washout of flumazenil from the primate brain in a dosedependent fashion. These findings would be consistent with the proposed GABA A allosteric modulator function of clarithromycin. While the results are only preliminary, further investigation of the interaction of clarithromycin with GABA receptors and/or GABAergic medications is warranted, and therapeutic applications of clarithromycin alone or in combination with flumazenil, to treat hyper-GABAergic status in PD at minimally effective doses, should also be pursued.

Recent Developments in Diagnosis of Epilepsy: Scope of MicroRNA and Technological Advancements

“…Flumazeline is a GABA A receptor ligand, also known as 11 C-flumazeline, which is vigorously used for ectopic focus determination [ 53 ]. The GABA receptor plays an important role in the pathology of epilepsy.…”

Pharmacokinetic Interaction After Oral Coadministration of Clarithromycin and the Tyrosine Kinase Inhibitor Lapatinib in Rats

“…Moreover, clarithromycin is a negative allosteric modulator of GABAA receptors, which might be significant in the treatment of e.g. hypersomnia (16). It is also applied in combination with naproxen and oseltamivir to elderly patients hospitalized due to the severe course of influenza with pneumonia (17).…”